Stryker (SYK) Q2 2026 earnings review
V-Shaped Recovery Shakes Off Cyber Disruption
Stryker delivered a textbook V-shaped recovery in Q2 following a devastating Q1 cyber incident. Organic sales snapped back to 9.0% growth, completely reversing the prior quarter's 2.4% slump. More impressively, the volume rebound flowed aggressively to the bottom line: adjusted operating margins expanded 170 basis points to 27.4%, and Adjusted EPS surged 17.9%. Management's decision to narrow and raise the floor of full-year guidance confirms that the underlying hospital capital equipment cycle remains highly durable.
🐂 Bull Case
A 170 bps expansion in adjusted operating margins to 27.4% proves the 'Stryker Offense' works. Pricing power and manufacturing efficiencies easily overpowered lingering tariff and input cost headwinds.
MedSurg posted 9.7% reported growth, driven by US Medical (+12.6%) and US Endoscopy (+10.2%). This indicates hospital capital budgets are absorbing higher rates with no signs of fatigue.
🐻 Bear Case
Despite broader strength, US Vascular collapsed 6.7% YoY to $250M. This exposes severe vulnerabilities and continued competitive pressures in the ischemic stroke portfolio.
The 9.0% organic growth looks great, but an unknown portion is simply Q1 deferred procedures and backlog fulfillment. H2 will reveal the true underlying run-rate.
⚖️ Verdict: 🟢
Bullish. Stryker proved its Q1 weakness was entirely structural (cyber incident), not fundamental. The ability to dramatically expand margins while recovering delayed volumes demonstrates elite operational control.
Key Themes
Cyber Recovery Drives V-Shaped Sales
The overriding driver of Q2 was the successful catch-up from the late-Q1 cyber attack. Organic sales accelerated from 2.4% in Q1 back to a normalized 9.0%. The recovery was notably strong in US Instruments (+8.4%) and US Trauma & Extremities (+12.5%), as deferred surgeries were finally completed and consigned inventory revenue was recognized.
Margin Expansion Overpowers Macro Headwinds
Management delivered a remarkable 170 basis point expansion in Adjusted Operating Margin (27.4% vs 25.7% a year ago). This indicates accelerating leverage. Stryker successfully pushed through modestly positive pricing, which alongside favorable business mix, completely neutralized the heavy ~$400M annualized tariff headwinds discussed in prior calls.
Surgical Robotics & Orthopaedics Cycle
The Mako ecosystem continues to pull through broader portfolio sales. US Knees grew a stable 6.2%, while the newly formed 'Ortho Tech' division (combining Mako/enabling tech with instruments) grew 9.5% in the US. Product innovations like the Pangea plating system and Mako RPS handheld represent multi-year growth runways.
US Vascular Continues to Lag
While the headline screams 'recovery,' a specific data point contradicts the positive narrative: US Vascular sales reversed course, falling 6.7% YoY to $250M. This validates prior-quarter concerns regarding intense competitive pressure in the ischemic stroke segment. The Inari acquisition is meant to bolster the broader cardiovascular play, but the legacy neurovascular unit is currently a dead weight.
Macro: Slower European Capital Budgets
International sales grew 11.0% reported, heavily aided by FX and specific regions like Japan, but underlying macro concerns persist in Europe. Previous commentary highlighted a 'slower capital environment in Europe' coupled with EU MDR regulatory delays. This remains a pocket of geographic friction limiting even faster international expansion.
Base Effect vs Structural Growth
It is mathematically impossible to untangle how much of Q2's 9.0% organic growth was pure structural demand versus one-time mechanical backlog fulfillment from Q1. If Q2 absorbed all the deferred Q1 capital equipment orders, Q3 could see a decelerating 'air pocket' in MedSurg.
Other KPIs
Calculated as Operating Cash Flow ($1,842M) less CapEx ($368M). Operating cash flow accelerated significantly, up 35.3% YoY from $1,361M in the first half of 2025. This robust cash generation easily covers the $674M paid in YTD dividends and shores up the balance sheet for further M&A 'firepower' (like the AVS integration).
Down 97% globally YoY due to the deliberate divestiture of the legacy Spinal implant business. This removes a low-growth, low-margin drag, allowing management to focus capital entirely on high-velocity robotics and enabling tech (Ortho Tech).
Guidance
Stable. The company narrowed its prior range of 8.0% - 9.5%, effectively raising the floor by 30 bps. The midpoint of 8.8% implies stable, upper-single-digit execution for the remainder of the year, signaling confidence that the Q1 disruption is entirely in the rearview mirror.
Accelerating. The floor was raised from $14.90, bumping the midpoint to $15.025. This represents an implied ~10.2% YoY growth over FY25's $13.63. The guide heavily relies on the assumption that FX stays slightly favorable and pricing remains modestly positive.
Key Questions
US Vascular Strategy
With US Vascular reversing 6.7% YoY, what specific competitive dynamics in the ischemic stroke market are driving this contraction, and what is the timeline for the product pipeline to stabilize this segment?
Q2 Catch-Up Quantification
How many basis points of the 9.0% organic growth in Q2 directly represent deferred procedures and make-to-order capital equipment delayed from Q1? Is there any residual catch-up spilling into Q3?
Capital Order Book Health
Given the surge in MedSurg and Endoscopy, are hospital CapEx commitments remaining 'elevated' going into H2, or are you seeing elongated sales cycles for major cash-purchase Mako deals?